NDA 050789 · Fresenius Kabi USA
Tobramycin Sulfate
Tobramycin Sulfate · Injection
Last checked: Nov 20, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jul 13, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
144
50 Phase 3, 6 recruiting
FAERS reports
12,545
10,114 serious, 1,303 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEPHROTOXICITY, OTOTOXICITY AND EMBRYO-FETAL TOXICITY WARNING: NEPHROTOXICITY, OTOTOXICITY, NEURO MUSCULAR BLOCKADE AND FETAL HARM See full prescribing information for complete boxed warning. Nephrotoxicity Tobramycin for Injection may cause acute kidney injury. Monitor renal function and serum tobramycin concentrations in all patients. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs. ( 5.1 ) Ototoxicity Tobramycin for Injection may cause irreversible auditory and vestibular toxicity. Monitor for symptoms of ototoxicity, and for renal function and serum tobramycin levels in all patients. Reduce the dose or discontinue the Tobramycin for Injection if impairment of renal function occurs. Discontinue Tobramycin for Injection if ototoxicity occurs. ( 5.2 ) Neuromuscular Blockade Aminoglycosides have been associated with neuromuscular blockade....
What it is approved for
From the label in effect Feb 7, 2024.
Tobramycin for Injection, is an aminoglycoside antibacterial indicated for the treatment of serious bacterial infections caused by susceptible isolates of the designated bacteria in the diseases listed below ( 1.1 ): Septicemia in the pediatric patient and adults caused by P. aeruginosa , E. coli , and Klebsiella species (spp). Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp., and Enterobacter spp. Skin, bone, and skin structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp., Enterobacter spp., and S. aureus. Complicated urinary tract infections caused by P. aeruginosa , Proteus spp., (indole-positive and indole-negative), E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., S. aureus , Providencia spp., and Citrobacter spp. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin for Injection and other antibacterial drugs, Tobramycin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.2 ). 1.1 Septicemia Tobramycin for Injection is indicated for the treatment of septicemia caused by susceptible isolates of P. aeruginosa, E. coli, and Klebsiella spp., in adult and pediatric patients. 1.2 Lower Respiratory Tract Infections Tobramycin for Injection is indicated for the treatment of lower respiratory tract infections caused by susceptible isolates of P. aeruginosa, Klebsiella spp., Enterobacter spp., Serratia spp., E. coli, and S. aureus in adult and pediatric...
Mechanism: Tobramycin sulfate is an aminoglycoside antibacterial drug [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TOBRAMYCIN SULFATE · TOBRAMYCIN SULFATE EQ 1.2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Ecological Effects of Decolonisation Strategies in Intensive CarePivotal-lookingCompleted
MJM BontenAcademic, hospital or other
NCT02208154 · 8,665 participants · Start Dec 1, 2013 · Primary completion Oct 27, 2017
Drug: Chlorhexidine oral care (CHX-Oro); Selective oropharyngeal decontamination (SOD) and 1 more · For: ICU-ecology (Multidrug Resistant Bacteria); ICU-acquired Bacteraemia
Sites: Edegem, Belgium; Ghent, Belgium; Liège, Belgium · 13 sites in all
- To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic SuspensionPivotal-lookingStatus unknown
Sutphin DrugsIndustry
NCT03975374 · 5,000 participants (planned) · Start Jun 15, 2019 · Primary completion Jul 1, 2019
Drug: Tobramycin/dexamethasone opthalmic solution; Tobradex Opthalmic Solution · For: Blepharo Conjunctivitis
Sites: Jamaica, New York
- Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRAPivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT04597008 · 1,660 participants · Start Jun 18, 2021 · Primary completion Jul 30, 2025
Drug: Treatment group; Control group · For: Post Operative Surgical Site Infection
Sites: Birmingham, Alabama; Los Angeles, California; Redwood City, California · 41 sites in all
- Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.Pivotal-lookingRecruiting
University Hospital, LinkoepingAcademic, hospital or other
NCT05169229 · 1,100 participants (planned) · Start Apr 1, 2022 · Primary completion Dec 2028
Drug: Vancomycin + Tobramycin; Saline · For: Arthroplasty, Replacement, Hip; Osteoarthritis, Hip; Antibiotic Resistant Infection and 1 more
Sites: Linköping, Sweden
- A Bioequivalence Study of Tobradex AFPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00362895 · 995 participants · Start Apr 2006 · Primary completion Aug 2006
Drug: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension; Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX) · For: Cataract
Sites: Fort Worth, Texas
- Perioperative SDD to Prevent Infectious Complications After EsophagectomyPivotal-lookingRecruiting
Radboud University Medical CenterAcademic, hospital or other
NCT05865743 · 854 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2027
Drug: SDD · For: Esophageal Cancer
Sites: Leuven, Belgium; Nijmegen, Netherlands
- Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract SurgeryPivotal-lookingCompleted
NTC srlIndustry
NCT03739528 · 808 participants · Start Sep 3, 2018 · Primary completion Dec 19, 2018
Drug: Levofloxacin + dexamethasone followed by dexamethasone; Tobramycin + Dexamethasone · For: Cataract
Sites: Ancona, Italy; Altamura, Italy; Bari, Italy · 57 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pneumonia782
- off label use778
- drug ineffective710
- acute kidney injury690
- dyspnoea688
- infective pulmonary exacerbation of cystic fibrosis624
- death482
- infection465
- hospitalisation462
- cough458
- condition aggravated451
- cystic fibrosis430
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 86 |
| 2005 | 104 |
| 2006 | 83 |
| 2007 | 133 |
| 2008 | 98 |
| 2009 | 104 |
| 2010 | 114 |
| 2011 | 213 |
| 2012 | 207 |
| 2013 | 171 |
| 2014 | 283 |
| 2015 | 449 |
| 2016 | 506 |
| 2017 | 561 |
| 2018 | 1,032 |
| 2019 | 1,557 |
| 2020 | 1,399 |
| 2021 | 1,030 |
| 2022 | 981 |
| 2023 | 832 |
| 2024 | 1,035 |
| 2025 | 894 |
| 2026 | 673 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tobramycin Sulfate (Tobramycin Sulfate)
2024 spending
$7.3M
Beneficiaries
5,660
12,737 claims
Per beneficiary
$1,298
$6.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,541,571 |
| 2021 | $8,011,124 |
| 2022 | $2,105,371 |
| 2023 | $1,953,192 |
| 2024 | $7,343,974 |
Part B: Tobramycin Sulfate (Tobramycin Sulfate) · HCPCS J3260
2024 spending
$68K
Beneficiaries
7,168
12,247 claims
Per beneficiary
$9
2024 ASP limit $2.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $56,438 |
| 2021 | $66,503 |
| 2022 | $61,825 |
| 2023 | $55,228 |
| 2024 | $67,742 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Effects of prophylactic nebulized antibiotics on the prevention of ICU-acquired pneumonia: a systematic review and meta-analysis.
Gao M, Yu X, Liu X, et al. · PeerJ 2024 · Systematic Review, Meta-Analysis
- Safety of topical tobramycin powder during operative treatment of fractures.
Schrank GM, O'Hara NN, Lee S, et al. · J Antimicrob Chemother 2025 · Observational Study, Randomized Controlled Trial
- Antibiotic-loaded calcium sulfate in clinical treatment of chronic osteomyelitis: a systematic review and meta-analysis.
Shi X, Wu Y, Ni H, et al. · J Orthop Surg Res 2022 · Meta-Analysis, Systematic Review
- Topical antibiotics for treating bacterial keratitis: a network meta-analysis.
Song A, Yang Y, Henein C, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.
Guan WJ, Xu JF, Luo H, et al. · Chest 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.